Advanced search
Publication Cover
Leukemia & Lymphoma Latest Articles
Submit an article Journal homepage
286
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Direct and indirect costs for patients with myeloproliferative neoplasms

Jingbo Yua Incyte Corporation, Wilmington, DE, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9819-0735View further author information
ORCID Icon,
James Nelsonb Merative, Ann Arbor, MI, USAORCID Iconhttps://orcid.org/0000-0002-4211-4730View further author information
ORCID Icon,
Taylor Marlinb Merative, Ann Arbor, MI, USAView further author information
,
Evan Braunsteina Incyte Corporation, Wilmington, DE, USAView further author information
&
Michelle Jerryb Merative, Ann Arbor, MI, USAORCID Iconhttps://orcid.org/0000-0003-1664-8090View further author information
ORCID Icon
Received 23 Jan 2024, Accepted 31 Mar 2024, Published online: 27 Apr 2024

References

  • Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
  • Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Land­mark survey. BMC Cancer. 2016;16(1):167. doi:10.1186/s12885-016-2208-2
  • Price GL, Davis KL, Karve S, et al. Survival patterns in United States (US) Medicare enrollees with non-CML myeloproliferative neoplasms (MPN). PLoS One. 2014;9(3):e90299. doi:10.1371/journal.pone.0090299
  • Rungjirajittranon T, Owattanapanich W, Ungprasert P, et al. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019;19(1):184. doi:10.1186/s12885-019-5387-9
  • Mehta J, Wang H, Fryzek JP, et al. Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma. 2014;55(10):2368–2374. doi:10.3109/10428194.2013.879127
  • Yu J, Parasuraman S, Paranagama D, et al. Impact of myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the Living With MPNs survey. BMC Cancer. 2018;18(1):420. doi:10.1186/s12885-018-4322-9
  • Yu J, Paranagama D, Geyer HL, et al. Relationship ­between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living With MPN patient survey. Ann Hematol. 2019;98(5):1119–1125. doi:10.1007/s00277-019-03610-4
  • Bankar A, Zhao H, Iqbal J, et al. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada. Leuk Lymphoma. 2020;61(8):1908–1919. doi:10.1080/10428194.2020.1749607
  • Christensen SF, Svingel LS, Kjaersgaard A, et al. Healthcare resource utilization in patients with myeloproliferative neoplasms: a Danish nationwide matched cohort study. Eur J Haematol. 2022;109(5):526–541. doi:10.1111/ejh.13841
  • US Census Bureau. March 2019 Annual Social and Economic Supplement (ASEC). Washington, DC: Bureau of the Census for the Bureau of Labor Statistics; 2019.
  • Fazal S, Miller CB, Mascarenhas JO, et al. Phlebotomy frequency and quality of life and productivity in patients with polycythemia vera: results from the MPN Landmark survey in the United States. Blood. 2015;126(23):5184–5184. doi:10.1182/blood.V126.23.5184.5184

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.